<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524497</url>
  </required_header>
  <id_info>
    <org_study_id>Trazodone_1</org_study_id>
    <nct_id>NCT01524497</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression</brief_title>
  <official_title>A Clinical Study on Efficacy And Safety of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression A Multicenter, Randomized, Double-Blind, Parallel Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to
      evaluate the efficacy and safety of trazodone hydrochloride prolonged-release tablets for
      treatment of depression in Chinese population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale-17 score</measure>
    <time_frame>six weeks</time_frame>
    <description>17-item Hamilton Depression Rating scale were evaluated at the basemline and six weeks after treatment, the changes were recorded and used as primary outcome measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HAMA-14 score</measure>
    <time_frame>Six weeks</time_frame>
    <description>Change from baseline in HAMA-14 score at Visit 6/final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Severity of illness and CGI-Global improvement</measure>
    <time_frame>Six weeks</time_frame>
    <description>CGI-Severity of illness and CGI-Global improvement at Visit 6/final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in evaluation of sleep quality and sexual dysfunction</measure>
    <time_frame>Six weeks</time_frame>
    <description>change from baseline in evaluation of sleep quality and sexual dysfunction at Visit 6/final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate changes of responders/patients</measure>
    <time_frame>Six weeks</time_frame>
    <description>rate of responders, defined as patients with a 50% improvement from baseline in the HAMD score at Visit6/final visit;or rate of patients with remission, defined as patients with HAMD score ≤7 at Visit 6/final visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>75mg tablet/150 mg tablet</description>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 65, males and females, outpatients or inpatients;

          2. Single episode or recurrent depression according to DSM-IV (Version 4) criteria;

          3. Scores &gt; 18 on 17-item HAM-D at screening and baseline visits with a decrease not
             exceeding 20% between the two visits;

          4. Symptoms of depression for at least 1 month;

          5. Patients or their dependents/guardians providing signed informed consent forms.

        Exclusion Criteria:

          1. Serious suicide attempts (≥ 3 on item 3 'Suicide' of HAMD);

          2. Depressive episode, with psychotic symptoms;

          3. Refractory depression;

          4. Depressive episode secondary to other mental or physical disorders;

          5. Bipolar disorder;

          6. Significant reduction in body weight and malnutrition induced by major depression;

          7. Serious or unstable heart, hepatic, renal, endocrine and hematologic disease or
             malignant tumors;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin LI, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lee's Pharmaceutical company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>losing interest and feelings of guilt</keyword>
  <keyword>poor concentration</keyword>
  <keyword>loss of appetite</keyword>
  <keyword>suicide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

